A high performance liquid chromatographic method is described for simultaneous estimation of amiodarone and its metabolite desethylamiodarone in plasma. After precipitation with acetonitrile, the separation of amiodarone, desethylamiodarone and internal standard was accomplished using reversed phase chromatography. The mobile phase, a combination of ammonium acetate (pH 3.5 adjusted with ortho phosphoric acid) and acetonitrile was run isocratically through a C18 analytical column. The UV detection was done at 242 and 247 nm for amiodarone and desethylamiodarone respectively. Analytical run time was 10 min. Mean recovery was 84% for 0.5 µg/ml concentrations. The assay exhibited good linear relationship between peak height ratios and plasma concentration. Quantification limit was at least 0.01 µg/ml of amiodarone and desethylamiodarone. Accuracy and precision were over the concentration range of 0.01-10 µg/ml. Assay was successfully applied to the measurement of amiodarone and its metabolite desethylamiodarone in human plasma of patients who were on long-term oral therapy on amiodarone.
Amiodarone hydrochloride is an iodinated benzofuran with a long elimination half life, large volume of distribution, derivative antiarrythmic agent. The drug differs structurally and erratic and sometimes incomplete bioavailability 6, 7 and pharmacologically from other currently available There is a need for estimation of inter individual variability antiarrhythmic agents. Amiodarone hydrochloride has been required to support therapeutic drug monitoring. Though an important drug for the treatment of supraventricular and many high performance liquid chromatographic (HPLC) ventricular arrhythmias, in short-term inpatient and longmethods of assay [8] [9] [10] [11] [12] [13] [14] [15] [16] for use in pharmacokinetic studies are term outpatient settings. It may also have a role in affecting available for determination of amiodarone in biological outcomes in patients at risk for arrhythmic events and specimens, as mentioned in Table 1 , they are complex, sudden death; its place among available therapies is being expensive, time consuming and use internal standards that
established in clinical trials 1 . The increase in amiodarone use has been prompted in large part by the realization that alternative antiarrythmic drugs are prone to increase in mortality in post myocardial infraction patients 2 . In contrast to these Type I agents, amiodarone appears to improve survival in patients after myocardial infarction 3 and with congestive heart failure 4 . Amiodarone thus shifted from an agent of last recourse to that of first line therapy 5 and its popularity has further increased by its rapidly growing use in the management of refractory atrial arrhythmias. Amiodarone possesses interesting pharmacokinetic profile *For correspondence E-mail: sdrajendran@rediffmail.com www.ijpsonline.com are expensive or not commonly available. There is a need for a simple method for the simultaneous estimation of amiodarone and its metabolite desethylamiodarone in human plasma.
Here, we describe a HPLC method for simultaneous estimation of amiodarone and its metabolite desethylamiodarone in human plasma. The method can be used in pharmacokinetic studies of amiodarone where multiple, serial blood sample collection is desired in individuals.
prepared. These solutions were stored at -20° until use. Amiodarone is known to remain stable for at least 3 mo under these conditions. The working standard solutions were prepared prior to use from the stock solution by sequential dilution with a combination of acetonitrile: water in 90:10 ratio to yield final concentrations of 10, 1, 0.1, 0.01, and 0.001 µg/ml of amiodarone. Similarly desethylamiodarone working standards were also prepared. The internal standard stock solution was prepared by dissolving 1 mg of etoricoxib in 100 ml of acetonitrile: water in 1:1 ratio. This solution was stored at
MATERIALS AND METHODS
-20° until use.
Amiodarone hydrochloride (Medreich, India), In a 2 ml micro-centrifuge tube, 500 µl of plasma was added desethylamiodarone (Sanofi-Aventis, Newcastle, UK) and along with 500 µl of internal standard solution. The plasma etoricoxib (Glenmark Pharmaceuticals, Mumbai) were proteins were precipitated by the addition of 500 µl of obtained as gift samples. Acetonitrile, triethylamine, acetonitrile, and then the tubes were vortex mixed for ammonium acetate, and ortho-phosphoric acid were 30 sec and centrifuged at 11 000×g for 8 min. The purchased from Qualigens Fine chemicals (Mumbai, supernatant was transferred to a clean, similarly labeled India). Water for analytical purpose was obtained from tube and was subsequently recentrifuged for 2 min. The Milli-Q RO system. resultant solution was injected in to the HPLC system.
Chromatographic conditions:
Assay parameters: The HPLC system consisted of a Shimadzu LC-10AT
The extraction efficiency was determined by comparing liquid chromatographic pump, SIL-10a auto sampler and the peak area of known amounts of amiodarone and SPD-10A UV/Vis UV absorbance detector (Shimadzu, desethylamiodarone (unextracted) in mobile phase directly Kyoto, Japan). Data collection, integration and calibration injected to peak areas of samples containing the same were accomplished using Class VP Chromatography Data amounts of amiodarone in plasma after extraction. System Version 4.2 computer software (Shimadzu, Kyoto, Japan). The chromatographic separations of amiodarone, Quantification was based on calibration curves constructed desethylamiodarone, and internal standard (etoricoxib) using peak area ratios of drug to internal standard vs. were accomplished using a 250 × 4.6 mm I.D Luna 5µ C18 nominal concentration. Intra-day reproducibility was tested analytical column (Phenomenex, USA). A Guard-Pak preby using four different concentrations (0.010, 0.100, 1, and column module (Phenomenex, USA) containing an ODS 10 µg/ml). The procedure was repeated on three separate cartridge insert was placed serially just before the days to allow determination of inter-day precision and analytical column. The mobile phase consisted of accuracy. Intra-day accuracy was estimated based on the acetonitrile: 10 mM ammonium acetate (pH 3.5) in a mean percentage error, and the inter-day accuracy was combination of 60:40 v/v. Before use the mobile phase was degassed by passing it through a 0.22 µm filter.
The mobile phase was pumped at an isocratic flow rate of 1 ml/min at room temperature. The UV detection wavelength was set at 242 nm and 247 in two channels. The wavelengths of 242 and 247 represented the UV maximum of amiodarone and desethylamiodarone, respectively, in acetonitrile: water in 1:1 ratio.
Assay procedure:
A stock solution representing 100 µg/ml of amiodarone was prepared in acetonitrile: water in 1:1 ratio. Similarly, a stock solution of desethylamiodarone was also calculated as the mean of the intra-day accuracy determinations. The precision, expressed as a percentage, was evaluated by calculating the intra-and inter-day relative standard deviations.
The standard drug solutions in varying concentrations ranging from 0.01 µg/ml to 10.0 µg/ml were examined by the assay procedure. The response factor was calculated. The calibration curve was plotted using response factor Vs concentration of the standard solutions. The calibration curve showed a linear response over the range of concentrations used in the assay procedure. The calibration curve passes through the origin, which justifies the use of single point calibration. corresponding to internal standard, plasma sample. The mean extraction efficiencies of amiodarone from 500 µl of plasma at concentrations of less than 14% for amiodarone and less than 19% for 0.01 µg/ml to 10 µg/ml were 90-92% and of desethylamiodarone ( Table 2 ). Over the range of desethylamiodarone were 90-93%. Good linear concentrations from 0.01-10 µg/ml, the intra-day accuracies relationship were obtained between peak area ratios and ranged from 90 to 99.7% for amiodarone and 91-98% for the corresponding plasma concentration over a range of desethylamiodarone, and average inter-day accuracy 0.01-10 µg/ml of amiodarone.
ranged from 93.2 to 98.3% for amiodarone and 91 to 98.1% for desethylamiodarone. Based on this data, the The inter-day and intra-day coefficients of variation were validated lower limit of quantification of the method was The intra-day and inter-day precision and accuracy data for the simultaneous analysis of amiodarone and desethylamiodarone from human plasma samples. *CV is coefficient of variation 0.01 µg/ml based on 500 µl of human plasma. In patients taking a dose of 50-400 mg/day of amiodarone, plasma samples were analyzed using the described HPLC
The HPLC method described here is accurate and precise, and is capable of determining concentrations of amiodarone and desethylamiodarone in small volumes of human plasma. The extraction procedure was simple and the procedure used a commercially available inexpensive internal standard (etoricoxib). The method performed well with respect to reproducibility and accuracy over the range of concentrations studied (Table 3 ). This assay method was rapid, simple, and accurate. The chromatographic run time was less than 10 min. The lower limits of quantification and the small plasma volume necessary for the assay were ideal for studying
